Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to study the safety and efficacy of daratumumab in inducing
complete or partial remission in people with proliferative glomerulonephritis with monoclonal
immunoglobulin deposits (PGNMID).